OpenURL Connection Search

Select item for more details and to access through your institution.

Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients.
Published in:
2012
By:
- Kanto T;
- Inoue M;
- Oze T;
- Miyazaki M;
- Sakakibara M;
- Kakita N;
- Matsubara T;
- Higashitani K;
- Hagiwara H;
- Iio S;
- Katayama K;
- Mita E;
- Kasahara A;
- Hiramatsu N;
- Takehara T;
- Hayashi N;
- Kanto, Tatsuya;
- Inoue, Michiyo;
- Oze, Tsugiko;
- Miyazaki, Masanori
Publication type:
journal article
The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1.
Published in:
Journal of Viral Hepatitis, 2015, v. 22, n. 3, p. 254, doi. 10.1111/jvh.12289
By:
- Oze, T.;
- Hiramatsu, N.;
- Yakushijin, T.;
- Yamada, R.;
- Harada, N.;
- Morishita, N.;
- Oshita, M.;
- Mita, E.;
- Ito, T.;
- Inui, Y.;
- Inada, M.;
- Tamura, S.;
- Yoshihara, H.;
- Imai, Y.;
- Kato, M.;
- Miyagi, T.;
- Yoshida, Y.;
- Tatsumi, T.;
- Kasahara, A.;
- Hayashi, N.
Publication type:
Article
Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.
Published in:
Journal of Viral Hepatitis, 2014, v. 21, n. 5, p. 357, doi. 10.1111/jvh.12151
By:
- Harada, N.;
- Hiramatsu, N.;
- Oze, T.;
- Morishita, N.;
- Yamada, R.;
- Hikita, H.;
- Miyazaki, M.;
- Yakushijin, T.;
- Miyagi, T.;
- Yoshida, Y.;
- Tatsumi, T.;
- Kanto, T.;
- Kasahara, A.;
- Oshita, M.;
- Mita, E.;
- Hagiwara, H.;
- Inui, Y.;
- Katayama, K.;
- Tamura, S.;
- Yoshihara, H.
Publication type:
Article
Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.
Published in:
Journal of Viral Hepatitis, 2010, v. 17, n. 5, p. 336, doi. 10.1111/j.1365-2893.2009.01182.x
By:
- Inoue, Y.;
- Hiramatsu, N.;
- Oze, T.;
- Yakushijin, T.;
- Mochizuki, K.;
- Hagiwara, H.;
- Oshita, M.;
- Mita, E.;
- Fukui, H.;
- Inada, M.;
- Tamura, S.;
- Yoshihara, H.;
- Hayashi, E.;
- Inoue, A.;
- Imai, Y.;
- Kato, M.;
- Miyagi, T.;
- Hohsui, A.;
- Ishida, H.;
- Kiso, S.
Publication type:
Article
Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin.
Published in:
Journal of Viral Hepatitis, 2009, v. 16, n. 8, p. 586, doi. 10.1111/j.1365-2893.2009.01106.x
By:
- Hiramatsu, N.;
- Oze, T.;
- Yakushijin, T.;
- Inoue, Y.;
- Igura, T.;
- Mochizuki, K.;
- Imanaka, K.;
- Kaneko, A.;
- Oshita, M.;
- Hagiwara, H.;
- Mita, E.;
- Nagase, T.;
- Ito, T.;
- Inui, Y.;
- Hijioka, T.;
- Katayama, K.;
- Tamura, S.;
- Yoshihara, H.;
- Imai, Y.;
- Kato, M.
Publication type:
Article
Pegylated interferon alpha-2b (Peg-IFN α-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN α-2b plus ribavirin.
Published in:
Journal of Viral Hepatitis, 2009, v. 16, n. 8, p. 578, doi. 10.1111/j.1365-2893.2009.01116.x
By:
- Oze, T.;
- Hiramatsu, N.;
- Yakushijin, T.;
- Kurokawa, M.;
- Igura, T.;
- Mochizuki, K.;
- Imanaka, K.;
- Yamada, A.;
- Oshita, M.;
- Hagiwara, H.;
- Mita, E.;
- Ito, T.;
- Inui, Y.;
- Hijioka, T.;
- Tamura, S.;
- Yoshihara, H.;
- Hayashi, E.;
- Inoue, A.;
- Imai, Y.;
- Kato, M.
Publication type:
Article

Found: 6

Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients.

The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1.

Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.

Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.

Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin.

Pegylated interferon alpha-2b (Peg-IFN α-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN α-2b plus ribavirin.